To find out more, watch the following video (4:27 min). A link to a transcript of the interview is also provided below. 

SmartTRAK: Hi, this is Sharon O'Reilly. I'm at the Canaccord Conference before the 2025 AAOS, and I ran into Alessandra Pavesio, who's so excited about her company, Doron Therapeutics.

So, Alessandra, why don't you tell us a little bit about the company and some of the exciting new developments.

Alessandra Pavesio: It's always great to see you, Sharon. I love bumping into you and having some really good news to deliver. First of all, what is Doron Therapeutics? It's a management-led spin-off. We really were passionate about a technology that we've developed with Bioventus, and when Bioventus divested from this program for financial considerations, we were able to negotiate a very favorable deal to actually set up a spin-off company and go raise private capital to invest in the program.

The good news is that, yes, we've set up a company. Yes, we have raised private capital. And so now we are really up and running and getting ready to start a Phase III study.

Big milestone that we've accomplished is that we've been recognized by FDA as an RMAT therapy. RMAT means Regenerative Medicine Advanced Therapy. As such, that means attention from senior officials at FDA that are really partnering with you to get this product to market for the patients that we serve. Super excited.

SmartTRAK: Tell us about the product.

AP: So our lead program is called MOTYS. It's placental-derived injectable therapeutic. It's a biological drug that ...

Click the button below to download and read the complete transcript of SmartTRAK's interview with Doron Therpeutics' CEO Alessandro Pavesio, conducted by Sharon O'Reilly, SmartTRAK Founder and CEO.

We are pleased to announce that John Hatchell has joined the team at SmartTRAK as Director of Sales for the Commercial team. John has 13 years of Medical Device sales and leadership experience within Orthopedics, helping to support trauma, joint replacement and robotics for Stryker and Biomet. Most recently, he has been the founder and CEO of TYDEi Health, a provider-focused business intelligence and optimization platform.

SmartTRAK highlights start-ups developing innovative products for joint resurfacing, soft tissue fixation, ligament and tendon augmentation at the 2023 MNVC.

Sports medicine and extremities were prominent themes at the 21st Annual Musculoskeletal New Ventures Conference (MNVC) held in Memphis in November 2023. Approximately one-third of the 38 presenting companies debuted new and innovative technologies for treating sports-related injuries of the knee, shoulder, hand, foot & ankle ranging from soft tissue fixation, ligament and tendon augmentation and cartilage resurfacing. Now that investment in robotics and surgical navigation craze has peaked, major orthopedic manufacturers are directing research and development (R&D) dollars toward restoring joint function using biological approaches and a variety of less invasive techniques. 

Among the topics covered in this market outlook article are:

• Promising Knee and Shoulder Start-Ups
• Extremity Fixation: An Emerging Market
• Resurgence in Joint Resurfacing

A fertile ground for strategic negotiations and deal-making, several of the major players have broadened their range of products through strategic tuck-in acquisitions in the past year. Also, several start-ups are targeting the multi-billion dollar Soft Tissue Fixation market.  This landscape reflects a dynamic and competitive environment where established players seek to strengthen their positions through ...

To download and read the complete "Sports Medicine and Extremities Start-Ups to Watch" market outlook article by Sharon O'Reilly, SmartTRAK's Founder and CEO, just click the button below.

As the CEO of SmartTRAK, I understand Medtech executives often drown in data and need quick, easy access to market insights from a trusted source. According to a Forbes article Big Data is Dead. Long Live Smart Data, the “more Data-is-Better” era is over, and it is time for Smart Data. And that means a SmartTRAK subscription is more important than ever.

SmartTRAK is the Medtech’s industry first and only “Insights-as-a-Service” (IaaS) solution, curating data from hundreds of data sources, including public and commercial databases as well as extensive attendance and coverage of industry conferences. Our team of industry experts and data scientists do the work for our customers, providing actionable intelligence and insights from data that is already cleaned, verified and featurized. Our proprietary data curation methodology powers the SmartTRAK platform, which can be accessed on demand 24x7 across the enterprise.

Do you love keeping up with the latest trends in the Spine and OrthoBiologics/Regen medicine markets? Are you a closet investigative reporter who loves researching and analyzing what’s going on in the market? Are you looking for a position that leverages your industry knowledge, expertise and connections in new ways? If you are a current or former marketing, market research or business development professional who has worked with one of the major orthopedic/spine companies and looking for a career change, we would love to talk with you.

We are looking to strengthen our SmartTRAK Spine and OrthoBiologics/Regen modules with the addition of a qualified person with industry specific experience. All SmartTRAK analysts are former marketing, business development or R&D professionals with one of the major orthopedic/spine suppliers and, in fact, most have come to us via recommendations from our subscribers, as well as those in the industry. We believe that having a person of this caliber with relevant experience and deep insight on the market is a tremendous value-add we can offer SmartTRAK subscribers.

We are looking for someone with Spine and OrthoBiologics/Regen industry experience who is interested in working full-time. Click the button below to learn more and apply.

Pete Wehrly, CEO of VIVEX Biologics, discusses the Company and its diverse portfolio in orthopedics and wound care in an interview with SmartTRAK

In an interview with SmartTRAK, VIVEX Biologics’ CEO Pete Wehrly discusses how VIVEX’ diverse portfolio of regenerative solutions in orthopedics and wound care can potentially turn the regenerative medicine industry on its ear with an eye towards proving, through economic and clinical evidence, that its technologies are better than anything on the market today.

To find out more about the Company, its technologies and what’s next in terms of clinical research and reimbursement, click on the following video to see the interview recorded live at the North American Spine Society (NASS) Annual Meeting held in Boston Sept 29 to Oct 2, 2021 (11:24 min). A link to download the complete transcript of the interview is also provided below.

We are looking to strengthen our SmartTRAK Spine module with the addition of a qualified person with industry specific experience. All SmartTRAK analysts are former marketing, business development or R&D professionals with one of the major orthopedic/spine suppliers and, in fact, most have come to us via recommendations from our subscribers, as well as those in the industry. We believe that having a person of this caliber with relevant experience and deep insight on the market is a tremendous value-add we can offer SmartTRAK subscribers.

We are looking for person with Spine industry experience who is interested in working approximately 20 hours per week. We would also consider a person who would like to work full-time.Ideally, this person has:

• Deep knowledge of the spine market, especially spine hardware
• Strong communication skills, especially writing
• Good analytical skills and experience with forecasting
• Attention to Detail
• Extensive contacts in the industry with both companies and clinicians

This is a great position for an experienced person who wants to remain in the game but wishes to work part-time.

We are pleased to announce that Gary Delhougne has joined the team at SmartTRAK as General Manager, Wound. Gary is a licensed attorney with 20 years’ medical device and consulting experience in market access, health economics and policy roles at Smith & Nephew, Covidien, Avalere Health and Ernst & Young.

Gary will be taking over for Susan Paquette, who is retiring at the end of the year. For the past 10 years, Susan has been the face of SmartTRAK Wound Care at industry meetings and has become a trusted advisor to many of our subscribers.

Gary will be representing SmartTRAK at SAWC Fall in Las Vegas, October 28-31. If you would like to meet with him to discuss the exciting new innovations ahead and learn how to network your entire organization with SmartTRAK, click the link below. To learn more about Gary, just keep reading!

Meet Gary Delhougne:

What is your role with SmartTRAK? As the General Manager of SmartTRAK’s Wound business, it is my role to lead the wound care team in delivering actionable business intelligence and decision-making tools to help our customers better serve patients and providers.

We are pleased to announce that Andy Knapik has joined the team at SmartTRAK as Senior Analyst, Soft Tissue Fixation and Arthroscopic Technologies. Andy has 20+ years’ experience in US and International sales and marketing for the orthopedics and sports medicine markets, including 12 years at Smith & Nephew.

Meet Andy Knapik:

What is your role with SmartTRAK? As Senior Analyst for Soft Tissue Fixation and Arthroscopic Technologies, I am currently developing and supporting the Arthroscopic Technologies module, which is new to SmartTRAK, as well as the Sports Medicine Repair module.

What do you like about SmartTRAK? I love the depth and range of experience of all of the analysts. There is a lot of industry knowledge that we can offer customers, and it’s really impressive to me.

What is something special or unique that you bring to SmartTRAK subscribers? I have 20 years of experience in orthopedics working with just about every product that an orthopedist would use from sports medicine and arthroscopy, to trauma and reconstruction. I have also worked in diverse geographies, working in both the US market and internationally in both established as well as emerging markets. So even though my current specialty lies in sports medicine and arthroscopy, there is quite a bit of cross over in general orthopedics that I am able to discuss.

2020 was a tumultuous year like no other, and SmartTRAK, the leading provider of real-time market data, analysis and advisory services for the orthopedic, wound, regenerative medicine and neuro therapies markets, was here to keep you informed of everything that transpired in the MedTech industry. SmartTRAK covered all the key happenings in 2020, providing comprehensive industry coverage of the latest trends, news, intel and interviews most important to you.

1) A Critical Crossroads for COVID-19: An Interview with Krishnan                             Chakravarthy
   by Anne Staylor, 3/23/20

Krishnan Chakravarthy, MD, PhD discusses the COVID-19 pandemic, current and evolving methods for containing and treating the virus, how it's changing the practice of pain medicine and its impact on industry in an interview with SmartTRAK.

2) Europe: New Routines in Greetings and in Wound Management 
     by Anikó Szekér, 12/21/20

SmartTRAK examines the Top 5 countries in Europe during the time of COVID-19 and estimates how the Advanced Wound Dressing Market will be impacted in 2020 and 2021.

3) What's New in Spine and Orthopedic Computer-Assisted Surgery (CAS)
     by Elise Wolf, 11/24/20

SmartTRAK highlights what’s new in the Spine and Orthopedic Computer-Assisted Surgery (CAS) markets.